BIO Sends Letter to President Trump on U.S.-China Trade & Biotech
December 18, 2018
BIO sent a letter to President Trump following his meeting with President Xi of the People’s Republic of China, welcoming the news the United States and China have begun talks to address important issues including forced technology transfer, intellectual property protection, and agriculture. BIO reminded President Trump of the need to resolve systemic barriers to China’s timely approvals of new agricultural biotechnology products, the approval of all pending products that have languished for years, and intellectual property rights protection of U.S. biomedical products are paramount to continued U.S. innovation, competitiveness, and export growth.
Dear Colleagues, I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has delivered one of the great…
BIO sent a letter to President Trump following his meeting with President Xi of the People’s Republic of China, welcoming the news the United States and China have begun talks to address important issues including forced technology transfer, intellectual property protection, and agriculture. BIO reminded President Trump of the need to resolve systemic barriers to China’s timely approvals of new agricultural biotechnology products, the approval of all pending products that have languished for years, and intellectual property rights protection of U.S. biomedical products are paramount to continued U.S. innovation, competitiveness, and export growth.